Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
Read why Lilly’s Hanmi sonefpeglutide deal could reshape long-acting GLP-2 therapy for short bowel syndrome.
Alcresta’s RELiZORB shows BMI and weight gains in pediatric tube-fed patients
See how RELiZORB improved weight and BMI z-scores in tube-fed children aged 1–5 in new real-world data. Explore what this means for pediatric care today.